Jim Cramer: Don't Buy Gilead on Remdesivir News

Jim Cramer weighs in on the positive news around Gilead's remdesivir.
Publish date:

Gilead released some positive news about remdesivir early Wednesday morning. 

The drugmaker was briefly halted in premarket trading and then released that remdesivir--its experimental drug--met a government study primary endpoint.

Remdesivir is being tested in multiple clinical trials and it is being used to treat severely ill COVID-19 patients who have been hospitalized.

The study is being conducted by the National Institute of Allergy and Infectious Diseases.

Remdesivir has been getting a slew of headlines--both good and bad--in the past couple of weeks.

Stat News reported positive findings based on a leaked video from a trial in Chicago on April 16 and then the World Health Organization accidentally posted a study on remdesivir from China, which reportedly showed that the drug wasn't helping to speed up the recovery of patients with COVID-19. Gilead had said, however, that the data noted a "potential benefit."

Watch the full video above for Cramer's full take.

Want to know what Jim Cramer and his team at Action Alerts PLUS are thinking about the markets and the stocks they're watching? Sign up on Action Alerts PLUS for more.

Cramer and the team are weighing in on what members need to know about the coronavirus pandemic's impact on the market. Here's how you can recap his entire April show.

Watch More of the Latest Videos on TheStreet and Jim Cramer

Jim Cramer: Apple Is Earnings Report to Watch This Week